PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
EBIT growth above 1.5x RVPH's 5.85%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-6.92%
Negative operating income growth while RVPH is at 7.11%. Joel Greenblatt would press for urgent turnaround measures.
121.05%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
121.15%
EPS growth above 1.5x RVPH's 7.69%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
115.11%
Diluted EPS growth above 1.5x RVPH's 7.69%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2.25%
Share count expansion well above RVPH's 2.47%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
42.15%
Diluted share count expanding well above RVPH's 2.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-3.22%
Negative OCF growth while RVPH is at 38.83%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-8.23%
Negative FCF growth while RVPH is at 38.83%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39049.73%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-717224.10%
Negative 5Y OCF/share CAGR while RVPH is at 21.52%. Joel Greenblatt would question the firm’s operational model or cost structure.
-12351.82%
Negative 3Y OCF/share CAGR while RVPH stands at 53.59%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
45138.86%
Positive 10Y CAGR while RVPH is negative. John Neff might see a substantial advantage in bottom-line trajectory.
41496.01%
5Y net income/share CAGR above 1.5x RVPH's 60.51%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
7331.25%
3Y net income/share CAGR above 1.5x RVPH's 58.01%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
8529.17%
Equity/share CAGR of 8529.17% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2357.47%
Equity/share CAGR of 2357.47% while RVPH is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
2495.43%
Positive short-term equity growth while RVPH is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Asset growth above 1.5x RVPH's 64.40%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
131.44%
1.25-1.5x RVPH's 89.95%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-41.82%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-18.65%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
44.07%
We expand SG&A while RVPH cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.